New £115m type 2 diabetes research centre
A pioneering research centre aimed at finding new treatments for type 2 diabetes will be built as part of a £115m collaboration between Novo Nordisk and a leading university.
Novo Nordisk has announced the partnership with the University of Oxford, which will allow scientists from both organisations to work together to come up with new ways of treating the condition.
Up to 100 Novo Nordisk researchers will be employed to work at The Novo Nordisk Research Centre Oxford based in an Oxford University research centre.
The collaboration will see researchers focus on news ways to make a difference on the future treatment of type 2 diabetes at an early stage.
Mads Krogsgaard Thomsen, Chief Science Officer and Executive Vice President of Novo Nordisk, said: “This collaboration brings together some of the world’s sharpest minds in the field of diabetes to seek new targets for therapeutic innovation. It combines Novo Nordisk’s 90 years’ experience in developing treatments for diabetes with the expertise of world leading scientists from the University of Oxford. Our vision is that the unique combination of industrial and academic know-how will eventually lead to a new generation of treatments to improve the lives of people with type 2 diabetes.”
The collaboration will actively seek to encourage cross-fertilisation of ideas between academic researchers from the University of Oxford and researchers employed by Novo Nordisk with funds to sponsor the collaborative research.
Sir John Bell, Regius Professor of Medicine, University of Oxford, said: “We see the collaboration with Novo Nordisk as an outstanding opportunity to mix competence embedded at our campus with Novo Nordisk’s groundbreaking research and results in diabetes. This collaboration underlines the importance of shared research and cutting-edge science across boundaries. Employees at Novo Nordisk Research Centre Oxford and researchers at the University of Oxford will have the opportunity for daily interaction to share knowledge and insights that will potentially produce new medicines for people living with type 2 diabetes and its complications”.
Professor James D. Johnson, has been appointed head of the Novo Nordisk Research Centre Oxford. He is a world-renowned researcher in the fundamental biology of pancreatic islets, insulin action, diabetes and related conditions, the company said.
Dr Johnson is currently Professor at the Department of Cellular and Physiological Sciences and the Department of Surgery at the University of British Columbia.
Novo Nordisk and University of Oxford have had a collaboration since 2013 through the International Postdoctoral Fellowship Programme. The programme was extended in 2015 and will include up to 32 fellows.